Medical cannabis flower costs considerably less in Germany than it did a year ago. According to data published on 3 November by Business of Cannabis, the average pharmacy price per gram fell from €7.70 to €6.00 between September 2025 and September 2026, a 22% drop, while the number of products on offer grew by 73%. On the same day, Global Cannabis Exchange (GCX) published its autumn report confirming the trend at wholesale level.
More products than patients
Germany’s medical flower catalogue grew from 1,378 to 2,381 SKUs in twelve months, based on data from the comparison sites Flowzz and MedCanOnestop and from online pharmacies. The most common price now sits just under €5 per gram. The figure needs careful reading: it is an average not weighted by sales volume, so it reflects what is on the shelf, not what actually sells.
The underlying diagnosis is simple. Supply is growing faster than patient numbers, and 80-90% of a market estimated at around €1.15bn is self-pay. Those patients compare prices and buy on volume, not on premium positioning.
Wholesale is falling even faster
According to the GCX report covered by MMJDaily, lower-end wholesale prices have dropped 30-35% since spring, and Germany shows the steepest decline of the four markets analysed. Current per-gram ranges:
- GACP flower: €0.40-1.20 below 20% THC; €0.80-2.00 above.
- EU-GMP flower: €0.85-1.95 below 20% THC; €1.30-3.15 above.
GCX attributes part of the reset to the end of statutory reimbursement for flower on 30 July, which affected around 65,000 patients and removed a reference price. Add global oversupply: Canada produces about 3,500 tonnes against roughly 1,100 tonnes of domestic demand. CEO Steve Clark sees this largely as a new baseline for commodity flower and does not expect a real recovery before the second half of 2027. The UK and Switzerland are the exceptions, with prices holding up.
Consolidation ahead
The squeeze is already showing. On 28 October, SynBiotic SE, one of Germany’s early cannabis groups, announced it would file for insolvency after failing to secure financing. Regulatory uncertainty adds to the pressure: the MedCanG amendment, which would require an in-person consultation before a first prescription and ban mail-order pharmacy dispensing, still has no vote date. Prohibition Partners estimates the market could shrink by up to 50% if it passes. In June, the Hesse state health authority also questioned whether GACP flower can be processed under GMP after long-distance transit.
What it means for operators
- Producers and exporters: selling undifferentiated GACP flower into Germany leaves less and less margin. EU-GMP certification and consistent cannabinoid profiles are what hold price.
- Distributors and importers: thinly capitalised intermediaries are the most exposed. Supply reliability is starting to matter more than price.
- Pharmacies: the VCA pharmacy association is already warning of margin pressure as demand shifts to self-pay.
- Investors: the analysis points to consolidation and a shift towards extracts and other formulations. There are buying opportunities, but also impaired assets.
The debate comes to Bilbao
Germany remains Europe’s largest medical market and the main destination for European production, including output from the Iberian peninsula. How to compete once price stops being a lever will be one of the conversations at Spannabis B2B Bilbao 2027, on 11 March in the BEC VIP Hall. If you grow, distribute or invest in medical flower, get your ticket or book a B2B table to meet buyers and suppliers who are already renegotiating their contracts.